Main Menu


Abiraterone was discovered at The Institute of Cancer Research in what is now the Cancer Research UK Cancer Therapeutics Unit.

Abiraterone, trade name 'Zytiga', was discovered and developed at the ICR

Professor Johann de Bono and his team at the ICR and The Royal Marsden NHS Foundation Trust carried out the initial clinical development on this drug, as well as leading the later-stage international clinical trials including the first trial that led to regulatory approval.

Abiraterone is now used as standard treatment either before or after chemotherapy and has extended the lives of thousands of men in the UK with advanced prostate cancer.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.